Defibrillation Threshold Testing After ICD Implantation in Patients with Chronic Kidney Disease

Area of Science:

• Cardiology
• Nephrology
• Medical Devices

Background:

• Routine defibrillation threshold (DFT) testing for implantable cardioverter-defibrillator (ICD) implantation is not recommended due to lack of proven benefit.
• Patients with severe chronic kidney disease (CKD) were excluded from previous trials, leaving their DFT testing outcomes unaddressed.
• Current international guidelines do not specify the impact of kidney function on DFT testing in CKD patients.

Purpose of the Study:

• To evaluate the success and safety of DFT testing in patients with CKD stages 1-5 undergoing primary transvenous ICD implantation.
• To determine if chronic kidney disease affects defibrillation efficacy and safety margins during ICD implantation.

Main Methods:

• Retrospective study of 451 patients (ages 55-80) with CKD stages 1-5 undergoing primary transvenous ICD implantation.
• Patients were stratified into three groups based on CKD stage (1-2, 3-4, and 5).
• Ventricular fibrillation was induced 827 times to assess DFT success and safety.

Main Results:

• No significant differences in ICD defibrillation success rates were found across CKD groups (p=0.262).
• DFT-related complications occurred in 3.5% of patients, primarily hypoxemia and atrial arrhythmias.
• 1.1% of patients required ICD or lead revision due to abnormal DFT test results.

Conclusions:

• No correlation was found between CKD severity and increased DFT or inadequate defibrillation safety margins.
• DFT testing is a feasible procedure with a low risk of serious complications in CKD patients when clinically indicated.
• Routine DFT testing is not considered necessary for patients with moderate to advanced CKD.